Cosette Pharmaceuticals, Inc. (“Cosette”) announced that the U.S. Food and Drug Administration (FDA) has approved abbreviated New Prescription (ANDA) for Metronidazole Gel USP, 1%.This launch will allow Cosette to continue to build on its unprecedented track record in quality and leverage its US-based manufacturing facility in Lincolnton, NC.
According to IQVIA™, annual sales in the US market for the 12 months ending December 2022 for Metronidazole Gel USP, 1% are estimated at approximately $17 million.“The continued approval and launches of our internal R&D programs highlight our commitment to world-class R&D and operational excellence. We are Innovating Every Day and are committed to growing our pipeline and portfolio of products through R&D and global business development partnerships”
Apurva Saraf, President and CEO of Cosette Pharma.
